Skip to main content
Log in

Treating refractory scleritis with infliximab

  • Letters
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Mychalova K, Lim L. Biologic agents in the management of inflammatory eye diseases. Curr Allergy Asthma Rep 2008;8:339–447.

    Article  Google Scholar 

  2. Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007;125:895–900.

    Article  CAS  PubMed  Google Scholar 

  3. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317–2323.

    Article  PubMed  Google Scholar 

  4. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252–257.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Won Ryang Wee.

About this article

Cite this article

Ahn, S.J., Oh, J.Y., Kim, M.K. et al. Treating refractory scleritis with infliximab. Jpn J Ophthalmol 53, 286–287 (2009). https://doi.org/10.1007/s10384-008-0652-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-008-0652-5

Key Words

Navigation